Evan Stein, MD, PhD
Metabolic & Atherosclerosis Research Center
Harry Leider, MD, MBA
Chief Medical Officer
CME and CPE, 1 hour
This is the
first program in a two-part series based on previously presented live audioconferences.
Treatment of dyslipidemia, specifically elevated low-density lipoprotein cholesterol (LDL-C), is now considered the core strategy to prevent coronary heart disease as its effectiveness has been demonstrated beyond refute. Several effective treatments proven to reduce LDL-C are now available. However, elevated LDL-C, especially in high-risk patients, continues to be suboptimally treated, resulting in enormous waste in terms of human cost and economic loss, to the healthcare system. Many patients are not being treated aggressively enough to achieve evidence-based target LDL-C goals as outlined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines and a more recently published update that specifies high-risk patients be targeted to an LDL-C level of <70 mg/dL. This online program will explore the evidence supporting these new targets, showing how and why lower LDL-C is indeed better and leads to more optimal outcomes and improved economic benefit to managed care and the entire healthcare system. Program Developer/Facilitator
. Target Audience
Managed Care Medical Directors, Pharmacy Directors, and other physicians and pharmacists interested in the management of dyslipidemia.
Upon completion of this educational activity, the participant should be able to:
Explain the evidence supporting the recently updated NCEP ATP III LDL-C goals and why these guidelines are important to managed care in terms of human cost and economic incentives.
Describe the necessity of determining individual prospective risk analysis for patients of high- and medium-risk status in order to guide treatment.
Restate the target goals advocated by the NCEP ATP III guidelines and the 2004 update published in Circulation.
It is the policy of AKH Inc. to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Stein discloses that he has received product consultation, advisory comittee, and speakers' bureau fees from AstraZeneca.
Dr. Leider discloses that his employer, XLHealth, is a disease management company that provides services to managed care organizations.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity. TM
AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been assigned the Universal Program Number 077-999-06-060-H01 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit.
Commercial Support Statements
This program is supported by an educational grant from AstraZeneca.
Please turn off all pop-up blockers.
Click on the “start program” icon. This will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or update/correct existing registration information. When ready, click on the “continue to program” icon at the bottom of the screen. This will take you to a brief pre-program survey.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking “start the virtual meeting” will allow you to begin the program presentation.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation. This will bring you to a brief post-program survey.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE statement of credit. Two attempts are allowed.
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.